• Please log in or register to access this feature.

Neurological Progress

Neuroimmunophilins: Novel neuroprotective and neuroregenerative targets

  1. Xin Guo PhD1,
  2. James F. Dillman III PhD1,
  3. Valina L. Dawson PhD1,2,3,*,
  4. Ted M. Dawson MD, PhD1,2

Article first published online: 2 APR 2001

DOI: 10.1002/ana.1030

Issue

Annals of Neurology

Annals of Neurology

Volume 50, Issue 1, pages 6–16, July 2001

Additional Information

How to Cite

Guo, X., Dillman, J. F., Dawson, V. L. and Dawson, T. M. (2001), Neuroimmunophilins: Novel neuroprotective and neuroregenerative targets. Ann Neurol., 50: 6–16. doi: 10.1002/ana.1030

Author Information

  1. 1

    Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD

  2. 2

    Department of Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, MD

  3. 3

    Department of Physiology, The Johns Hopkins University School of Medicine, Baltimore, MD

*Departments of Neurology and Neuroscience, The Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Carnegie 214, Baltimore, MD 21287

Publication History

  1. Issue published online: 26 JUN 2001
  2. Article first published online: 2 APR 2001
  3. Manuscript Accepted: 27 JAN 2001
  4. Manuscript Revised: 22 JAN 2001
  5. Manuscript Received: 17 NOV 2000

Funded by

  • USPHS. Grant Number: NS38377
  • Edward D. and Anna Mitchell Family Foundation

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (2032K)

Abstract

Cyclosporin A (CsA) and FK506 (tacrolimus) are immunosuppresants that are widely used in organ transplantation. CsA is an 11-member cyclic peptide, whereas FK506 is a macrolide antibiotic. Recently, these powerful and useful compounds have become of great interest to neuroscientists for their unique neuroprotective and neuroregenerative effects. These drugs and nonimmunosuppressive analogs protect neurons from the effects of glutamate excitotoxicity, focal ischemia, and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic cell death. They also stimulate functional recovery of neurons in a variety of neurologic injury paradigms. These drugs exert their effects via immunophilins, the protein receptors for these agents. The immunophilin ligands show particular promise as a novel class of neuroprotective and neuroregenerative agents that have the potential to treat a variety of neurologic disorders.

View Full Article (HTML) Get PDF (2032K)